Mira Pharmaceuticals (MIRA) Income Statement (2022 - 2026)
Income Statement report data from Mar 31, 2022 to Mar 31, 2026 for Mira Pharmaceuticals (MIRA).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Expenses | |||||||||||||||
Research And Development | 520K (+4.00%) | 500K (+21.95%) | 410K (-18.00%) | 500K (+61.29%) | 310K (-71.03%) | 1.07M (+75.41%) | 610K (-19.74%) | 760K (-25.49%) | 1.02M | -100.00K | 270K (-83.54%) | 1.64M (+130.99%) | 710K | - | - |
Selling General And Administrative | 580K (-89.12%) | 5.33M (+492.22%) | 900K (-14.29%) | 1.05M (-29.53%) | 1.49M (+47.52%) | 1.01M (-9.82%) | 1.12M (+10.89%) | 1.01M (-52.80%) | 2.14M (+100.00%) | 1.07M (+75.41%) | 610K (-8.96%) | 670K (-9.46%) | 740K (-53.46%) | 1.59M | - |
Operating Expenses | 1.10M (-81.10%) | 5.82M (+340.91%) | 1.32M (-14.84%) | 1.55M (-14.36%) | 1.81M (-12.98%) | 2.08M (+20.23%) | 1.73M (-2.26%) | 1.77M (-43.99%) | 3.16M (+225.77%) | 970K (-27.61%) | 1.34M (-52.48%) | 2.82M (+55.80%) | 1.81M (-25.21%) | 2.42M | - |
Operating Income | |||||||||||||||
Ebit | -1.15M (-80.70%) | -5.96M (+422.81%) | -1.14M (-25.97%) | -1.54M (-14.92%) | -1.81M (-12.98%) | -2.08M (+20.23%) | -1.73M (-2.26%) | -1.77M (-43.99%) | -3.16M (+225.77%) | -970.00K (-27.61%) | -1.34M (0.00%) | -1.34M (-25.97%) | -1.81M (-25.21%) | -2.42M (+63.51%) | -1.48M |
EBITDA | -1.15M (-80.70%) | -5.96M (+422.81%) | -1.14M (-25.97%) | -1.54M (-14.92%) | -1.81M (-12.98%) | -2.08M (+20.23%) | -1.73M (-2.26%) | -1.77M (-43.99%) | -3.16M (+225.77%) | -970.00K (-27.61%) | -1.34M (0.00%) | -1.34M (-25.97%) | -1.81M (-25.21%) | -2.42M (+63.51%) | -1.48M |
Other Income / Expenses | |||||||||||||||
Interest Expense | - | 20K | - | - | -20.00K (-50.00%) | -40.00K (0.00%) | -40.00K (-20.00%) | -50.00K | 430K (+43.33%) | 300K | - | 10K | - | - | - |
Net Interest Income | - | -20.00K | - | - | 20K (-50.00%) | 40K (0.00%) | 40K (-20.00%) | 50K | -430.00K (+43.33%) | -300.00K | - | -10.00K | - | - | - |
Other Non Operating Income | -50.00K | 50K (-72.22%) | 180K | - | 20K (-50.00%) | 40K | - | - | - | - | - | - | - | - | - |
Net Income | |||||||||||||||
Net Income From Continuing Operations | -1.15M (-80.77%) | -5.98M (+424.56%) | -1.14M (-25.97%) | -1.54M (-13.48%) | -1.78M (-12.75%) | -2.04M (+20.71%) | -1.69M (-1.74%) | -1.72M (-52.09%) | -3.59M (+182.68%) | -1.27M (-5.22%) | -1.34M (-0.74%) | -1.35M (-25.41%) | -1.81M (-25.21%) | -2.42M (+63.51%) | -1.48M |
Net Income | -1.15M (-80.77%) | -5.98M (+424.56%) | -1.14M (-25.97%) | -1.54M (-13.48%) | -1.78M (-12.75%) | -2.04M (+20.71%) | -1.69M (-1.74%) | -1.72M (-52.09%) | -3.59M (+182.68%) | -1.27M (-5.22%) | -1.34M (-0.74%) | -1.35M (-25.41%) | -1.81M (-25.21%) | -2.42M (+63.51%) | -1.48M |